- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00598351
Naturgeschichte-Studie von Patienten mit Neurofibromatose Typ 2
Eine prospektive Studie zum natürlichen Verlauf von Patienten mit Neurofibromatose Typ 2 (NF2).
Objective
With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.
Study Population
A total of 269 participants, ages 8-75, with a clinical or genetic diagnosis of NF2 will participate in this study.
Design
Study participants will be evaluated with a thorough physical and neurologic examination upon enrollment. This initial outpatient evaluation will include magnetic resonance imaging with contrast of brain and spine and blood collection for research use. Participants with measurable hearing will have audiology assessment performed. Participants with untreated vestibular schwannomas will have vestibular assessment performed during the initial visit. Genetic studies performed outside will be acceptable as confirmation of NF2 in enrolled patients. If needed to confirm NF2 with genetic studies, or for research purpose, whole genome/whole exome sequencing may be performed on blood obtained from subjects enrolled in this study. All participants will be evaluated by a speech language pathologist.
Subjects will be followed as outpatients for up to ten years, during which clinical, and radiologic evaluation will be performed annually. Auditory testing will be performed annually for participants with measurable hearing. Participants with initially untreated vestibular schwannomas will be followed annually with vestibular testing. Speech and swallowing reassessments will be repeated if worsening of speech or swallowing is reported. Blood will be collected at each visit for blood biomarker testing
Outcome measures
We hope to understand the biologic basis for speech and swallowing dysfunction in patients with NF2. We will study and report the strength of association of MRI findings, clinical assessments cranial nerve deficits and speech/swallowing dysfunction. We hope to
identify imaging biomarkers of hearing loss in NF2. We will attempt to discover the mode of peripheral neuropathy in patients with NF2. Lastly, we will attempt to discover previously unknown serum biomarkers associated with high tumor burden in NF2.
...
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Objective
With this prospective natural history study on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.
Study Population
A total of 269 participants, ages 8-75, with a clinical or genetic diagnosis of NF2 will participate in this study.
Design
Study participants will be evaluated with a thorough physical and neurologic examination upon enrollment. This initial outpatient evaluation will include magnetic resonance imaging with contrast of brain and spine and blood collection for research use. Participants with measurable hearing will have audiology assessment performed during the initial visit. Participants with untreated vestibular schwannomas will have vestibular assessment performed during the initial visit. Genetic studies performed outside will be acceptable as confirmation of NF2 in enrolled patients. If needed to confirm NF2 with genetic studies, or for research purpose, whole genome/whole exome sequencing may be performed on blood obtained from subjects enrolled in this study. All participants will be evaluated by a speech language pathologist.
Subjects will be followed as outpatients for up to ten years, during which clinical, and radiologic evaluation will be performed annually. Auditory testing will be performed annually for participants with measurable hearing. Participants with initially untreated vestibular schwannomas will be followed annually with vestibular testing. Speech and swallowing reassessments will be repeated if worsening of speech or swallowing is reported. Blood will be collected at each visit for blood biomarker testing
Outcome measures
We hope to understand the biologic basis for speech and swallowing dysfunction in patients with NF2. We will study and report the strength of association of MRI findings, clinical assessments cranial nerve deficits and speech/swallowing dysfunction. We hope to
identify imaging biomarkers of hearing loss in NF2. We will attempt to discover the mode of peripheral neuropathy in patients with NF2. Lastly, we will attempt to discover previously unknown serum biomarkers associated with high tumor burden in NF2.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Prashant Chittiboina, M.D.
- Telefonnummer: (301) 496-2921
- E-Mail: prashant.chittiboina@nih.gov
Studieren Sie die Kontaktsicherung
- Name: Christina P Hayes, C.R.N.P.
- Telefonnummer: (301) 496-2921
- E-Mail: christi.hayes@nih.gov
Studienorte
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- Rekrutierung
- National Institutes of Health Clinical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
subjects with a diagnosis of NF2 by established clinical criteria or genetic testing
Beschreibung
- INCLUSION CRITERIA:
To be eligible for entry into the study, candidates must meet all the following criteria:
- Have the diagnosis of NF2 by established clinical criteria or genetic testing.
- Be between the age of 8 and 75.
- Have the capacity to undergo serial MRI scanning of the CNS without IV sedation.
- Able to give informed consent, or have a parent able to provide informed consent if a child.
EXCLUSION CRITERIA:
Candidates will be excluded if they:
- Have a clinically unstable condition that precludes serial clinical and imaging evaluation (i.e. Class 3 congestive heart failure, severe chronic renal insufficiency, severe chronic obstructive pulmonary disease).
- Cannot have an MRI scan due to an allergy or relative contraindication to MRI contrast agents, prior surgery or implant that involves metal clips or wires, which might be expected to cause tissue damage or produce image artifacts such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, and artificial heart valves.
- ABIs or cochlear implants are not approved by the NIH Radiology department for safe use on NIH scanners..
- Have severe chronic renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73 m2), hepatorenal syndrome or post-liver transplantation.
- Are pregnant at time of intake visit (women of childbearing age will be tested with a urine pregnancy test).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Patients
Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To determine the natural history (clinical and radiographic) of nervous system tumors in NF2
Zeitfenster: annual for up to 10 years
|
Clinical Variables (longitudinal: measured annually for each subject)a. Subjective speech and swallowing dysfunction (binary)b. Spinal cord function:Modified ASIA Motor Scalec. Ambulatory status:modified McCormick grading scaled. Overall function:Karnofsky Performance Statuse. NFTI-QOLf. Functional Independence Measure scale MRI Variables (longitudinal: measured annually for each subject):a. Tumor volume (continuous variable) for VS tumors, meningiomas, other schwannomas, ependymomas, and Total tumor burden (number and volume). Specific growth rates of tumors.b. FLAIR hyper-intensity MRI Variables (cross-sectional: measured at baseline and as needed for each subject):c. MRI of Right Upper and Lower Extremity Laboratory testing variables (longitudinal:measured annually for each subject):a. Audiometry Laboratory testing variables (cross-sectional:measured at baseline and as needed for each subject)b. EMG/NCV study valuesc. Vestibular testing Covariate variable:a. Ageb. Sex |
annual for up to 10 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To identify the underlying causes, and patterns of progression of speech and swallowing problems in patients with NF2
Zeitfenster: Annual for up to 10 years
|
Self-reported swallowing deficits (binary, yes vs no) based on the last Visit (cross-sectional data) |
Annual for up to 10 years
|
|
To identify imaging biomarkers of hearing loss in patients with NF2
Zeitfenster: Annual for up to 10 years
|
MRI Variables (longitudinal: measured annually for each subject):a. Tumor volume (continuous variable) for VS tumors, meningiomas, other schwannomas, ependymomas, and Total tumor burden(number and volume). Specific growth rates of tumors.b. FLAIR hyper-intensity MRI Variables (crosssectional: measured at baseline and as needed for each subject |
Annual for up to 10 years
|
|
To identify the etiology of peripheral neuropathy in patients with NF2
Zeitfenster: Annual for up to 10 years
|
MRI images of the Right upper extremity will be evaluated for the presence of peripheral nerve lesions at baseline. These imaging findings will be evaluated with respect to EMG/NCV results. |
Annual for up to 10 years
|
|
To identify serum biomarkers of NF2 disease progression
Zeitfenster: Annual for up to 10 years
|
determination of serum biomarker status and suspected biologic markers of disease progression using quantitative immunoassay or newer proteomic approaches |
Annual for up to 10 years
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Prashant Chittiboina, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Neubildungen nach Standort
- Neubildungen
- Genetische Krankheiten, angeboren
- Neubildungen nach histologischem Typ
- Neurodegenerative Krankheiten
- Neubildungen, Drüsen und Epithelien
- Otorhinolaryngologische Erkrankungen
- Gliom
- Neubildungen, Neuroepithel
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neubildungen des Nervensystems
- Heredodegenerative Erkrankungen, Nervensystem
- Neubildungen der Nervenhülle
- Neoplastische Syndrome, erblich
- Neurokutane Syndrome
- Neubildungen des peripheren Nervensystems
- Neuroendokrine Tumoren
- Ohrenkrankheiten
- Otorhinolaryngologische Neubildungen
- Neubildungen, Gefäßgewebe
- Meningeale Neubildungen
- Neubildungen des zentralen Nervensystems
- Erkrankungen der Hirnnerven
- Erkrankungen des Rückenmarks
- Neurom
- Neubildungen der Hirnnerven
- Vestibulocochlea-Nervenerkrankungen
- Retrocochleäre Erkrankungen
- Neurofibrom
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Neurofibromatosen
- Meningiom
- Ependymom
- Neurilemmom
- Neurom, Akustik
- Neubildungen des Rückenmarks
Andere Studien-ID-Nummern
- 080044
- 08-N-0044
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .